Psoriasis Clinical Trial
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
Summary
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
Eligibility Criteria
Inclusion Criteria:
Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug)
Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline/Day 1 (prior to first dose of study drug)
Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug)
Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)
Exclusion Criteria:
Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed
Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis
Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA)
Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).
Have taken Apremilast (Otezla) within 3 months of first dose of study drug.
Have undergone treatment with tofacitinib within 3 months of first dose.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 40 Locations for this study
Rogers Arkansas, 72758, United States
Anaheim California, 92801, United States
Encinitas California, 92024, United States
Sacramento California, 95819, United States
Santa Ana California, 92701, United States
Santa Monica California, 90403, United States
Santa Monica California, 90404, United States
Orange Park Florida, 32073, United States
Orange Park Florida, 32073, United States
Tampa Florida, 33609, United States
Tampa Florida, 33609, United States
Tampa Florida, 33624, United States
West Dundee Illinois, 60118, United States
Indianapolis Indiana, 46256, United States
Indianapolis Indiana, 46256, United States
East Windsor New Jersey, 08520, United States
New York New York, 10065, United States
Rochester New York, 14623, United States
Chapel Hill North Carolina, 27514, United States
Chapel Hill North Carolina, 27516, United States
Chapel Hill North Carolina, 27599, United States
Oklahoma City Oklahoma, 73112, United States
Tulsa Oklahoma, 74136, United States
Rapid City South Dakota, 57702, United States
Houston Texas, 77004, United States
San Antonio Texas, 78213, United States
San Antonio Texas, 78213, United States
San Antonio Texas, 78218, United States
Norfolk Virginia, 23502, United States
Spokane Washington, 99202, United States
Winnipeg Manitoba, R3M 3, Canada
Markham Ontario, L3P 1, Canada
Oakville Ontario, L6J 7, Canada
Peterborough Ontario, K9J 5, Canada
Richmond Hill Ontario, L4B 1, Canada
Waterloo Ontario, N2J 1, Canada
Sherbrooke Quebec, J1L 0, Canada
Quebec , G1V4X, Canada
Gdansk , 80-26, Poland
Gdansk , 80-54, Poland
Lodz , 90-43, Poland
Torun , 87-10, Poland
Warszawa , 02-10, Poland
Wroclaw , 51-68, Poland
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.